KTRA | Kintara Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.2049 - 0.2356
52 Week Range	0.2049 - 26.21
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	3,552,720
Average Volume	83,392
Shares Outstanding	55,660,600
Market Cap	11,989,293
Sector	Healthcare
Industry	Biotechnology
IPO Date	2013-02-22

Valuation
Profitability
Growth
Health
P/E Ratio	-0.02
Forward P/E Ratio	N/A
EPS	-11.20
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	1
Country	USA
Website	KTRA

Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a photodynamic therapy for the treatment of cutaneous metastatic breast cancer. The company has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.

KTRA's peers: DYAI, TOVX

*Chart delayed

Analyzing fundamentals for KTRA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see KTRA Fundamentals page.

Watching at KTRA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on KTRA Technicals page.